Tumor-associated autoantibodies in clinical practice may be of use to stratify patients and their immunological responses [32], early-on the high prevalence of autoantibodies against proteins such as p53, c-myc, HER2, NY-ESO-1, CAGE, MUC1, and GBU4-5 [33,34]. Here, MUC1 is linked to neoplasm.